|
|
|
|
Compared with baseline, the topiramate group had selective, statistically significant declines on measures of attention and work fluency at acute doses, whereas the other two AED groups had no performance changes. At the 2- and 4-week test periods, only the topiramate subjects continued to display neurocognitive effects from drug administration. Results demonstrate potential acute and steady-state adverse cognitive effects from topiramate, whereas minimal efforts were displayed for either gabapentin or lamotrigine in young healthy adults. |
|